FILE:EW/EW-8K-20081114144145.txt.gz
EVENTS:	Other Events
TEXT:
ITEM: Other Events
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported): 
November 13, 2008
 
(949) 250-2500
Registrant's telephone number, including area code
 
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
           
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
           
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
           
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
o
           
 
Item 8.01.
             
Other Events.
 
On November 13, 2008, at a regular meeting of the Board of Directors of Edwards Lifesciences Corporation, Robert A. Ingram, a member of the Company's Board of Directors, was appointed to the Audit and Public Policy Committee, effective immediately, filling the vacancy created by the death of Philip M. Neal.
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 


